Scientists appear to be thisclose to having a fully pre-tested new technique for combatting ALL SARS VIRUSES, including Covid but also working on prior SARS viruses, and having implicit strengths that they expect to work on future SARS viruses that might otherwise cause a pandemic. If this is correct, as the highly detailed and well-supported research study seems to suggest, then we might be looking at the last SARS pandemic, EVER. Quite simply, scientists have identified a form of nanoparticle, called evACE2 that has worked very well in laboratory animals. Human clinical trials have yet to start, but the theory behind the technique appears to be likely to carry over to humans—in this case blood is blood is blood, regardless of mammalian species.
The article is this:
Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2
Here is the abstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the pandemic of the coronavirus induced disease 2019 (COVID-19) with evolving variants of concern. It remains urgent to identify novel approaches against broad strains of SARS-CoV-2, which infect host cells via the entry receptor angiotensin-converting enzyme 2 (ACE2). Herein, we report an increase in circulating extracellular vesicles (EVs) that express ACE2 (evACE2) in plasma of COVID-19 patients, which levels are associated with severe pathogenesis. Importantly, evACE2 isolated from human plasma or cells neutralizes SARS-CoV-2 infection by competing with cellular ACE2. Compared to vesicle-free recombinant human ACE2 (rhACE2), evACE2 shows a 135-fold higher potency in blocking the binding of the viral spike protein RBD, and a 60- to 80-fold higher efficacy in preventing infections by both pseudotyped and authentic SARS-CoV-2. Consistently, evACE2 protects the hACE2 transgenic mice from SARS-CoV-2-induced lung injury and mortality. Furthermore, evACE2 inhibits the infection of SARS-CoV-2 variants (α, β, and δ) with equal or higher potency than for the wildtype strain, supporting a broad-spectrum antiviral mechanism of evACE2 for therapeutic development to block the infection of existing and future coronaviruses that use the ACE2 receptor.
I don’t claim to understand everything I am reading here, but to me this is consistent with the rapid advance in disease-fighting medical technology that appears to be at our door—actually starting with the rapid development of vaccines for Covid-19. We should see some of the same in terms of genetics-based development of other disease fighters, such as antibiotics.